Cytokinetics CEO: Optimism still there despite ALS drug study failure

Cytokinetics President and CEO Robert Blum speaks to CNBC's Meg Tirrell about the failure of the company's late-stage ALS drug trial and what he sees in future therapies for the disease.
03:11
Tue, Nov 21 20172:48 PM EST